Ensights

Freezing down bulk drug substance (BDS) isn’t something you can play around with. This is a high value product where any failure or contamination due to the bag breaking can lead to delays in medicine getting to the patient. Making sure you pick the right solution to protecting that product makes a big difference. Here are three questions you should be considering:

The impact of the freeze/thaw process on workflows requires it be treated as a unit operation of its own.

As a partner, Entegris is continuously developing solutions for our customers’ biggest challenges. An unprecedented pandemic came with a one-of-a-kind challenge: help a leading COVID-19 vaccine manufacturer scale up their process.

The pharmaceutical and biopharmaceutical industries continue to embrace the utilization of single-use systems (SUS). With the ever-growing adoption of SUS products, increasing scrutiny has been placed on the purity concerns of single-use components and their possible impact on the biomanufacturing, storage and transportation of high value final products.

Entegris Highlights 2019 2019 was a year of exciting change and significant accomplishments for Entegris including strategic acquisitions, supplier awards, footprint expansions and technology center openings, sustained Five+ Sigma quality levels, hundreds of issued technology patents, and so much more!